Soheil Meshinchi

Appointments and Affiliations
 
 
Fred Hutchinson Cancer Research Center
Pediatric Hematology and Oncology
Clinical Research
Associate Member
Seattle Children's Hospital
Pediatric Hematology and Oncology
Pediatric Oncology/ Stem Cell Transplantation
Associate Professor and Attending Physican
University of Washington
Pediatric Hematology and Oncology
Pediatric Hematology/ Stem Cell Transplantation
Associate Professor
 Professional Headshot of Soheil Meshinchi

Mailing Address

Fred Hutchinson Cancer Research Center
Clinical Research Division
1100 Fairview Ave. N.
Mail Stop D5-380
Seattle, Washington 98109
United States

Contact

Phone: (206) 667-4077
Fax: (206) 667-4310
smeshinc@fhcrc.org

Degrees

Fellowship Training, University of Washington, Pediatic Hematology and Oncology, 2000.
Fellowship Training, Fred Hutchinson Cancer Research Center, Pediatic Hematology and Oncology, 2000.
Residency Training, Johns Hopkins Hospitals, Pediatrics, 1997.
M.D., Wayne State University, 1994.
Ph.D., University of Michigan, Pharmacology/Protein Biochemistry, 1990.

Research Interests

A. Clinical Expertise:
- Identification and therapy of high-risk leukemias
- Management of post transplant relapse in childhood leukemias
- Stem cell transplantation in leukemias
- Therapy of relapsed AML
- Targeted therapy in pediatric AML

B. Laboratory Interests:

Genomic alterations in AML and their role in the Pathogenesis of AML
- Biologic implications of disease associated mutations in AML
- Prelavence and clinical significance of FLT3 and other RTK mutations in AML
- Biologic consequence of RTK mutations in normal and malignant hematopoiesis

TARGET Initiative
- TARGET (Therapeutically Applicable Research to Generate Effective Treatments) Initiative, seeks to identify valid therapeutic targets so that new, more effective treatments can be developed for children with cancer. AML is one of the 5 diseases selected for comprehensive mutli-platform genomic and epi-genomic evaluation to identify biomarkers associated with disease outcome as well those who are viable candidates for targeted therapy. As part of this initiative, several hundred specimens from children with AML will undergo whole genome, whole transcriptome and exome capture sequencing to identify disease associated alterations. Upstream gene, transcript, methylation and miRNA profiling will be performed for integration with the sequencing data. Identified biomarkers will be rapidly validated and translated into clinical application.

Identification of novel markers of high risk disease in AML.
- Using state of the art molecular biologic techniques putative high risk markers are being identified and validated in a large cohort of pediatric and adult AML patients. This information will be used to create a patient-specific risk profile to be used in treatment assignment

Minimal Residual Disease (MRD) as a marker of high-risk disease in Pediatric AML
- Evaluation of flow cytometric evidence of MRD and its correlation with outcome
- Evaluation of molecular evidence of MRD and correlation with outcome
- Stem Cell origin of myeloid leukemias and role of RTK mutations in the evolution of AML
- Role of activating mutations of the signal transduction pathway in myeloid malignancies

Languages

Reading, Writing, Speaking

Farsi: Functional, Functional, Fluent

Memberships

American Society of Clinical Oncology
American Society of Hematology
Children's Oncology Group Myeloid Disease Committee
Childrens Oncology Group

Honors and Awards

Jose Carrera's International Leukemia Fellow, Jose Carrera's Leukemia Foundation, Fred Hutchinson Cancer Research Center, Molecular Pathogenesis of FLT3 Mutations in AML
Child Health Research Center Scholar, National Institutes of Health (NIH), University of Washington
COG Young Investigator Award, Childrens Oncology Group

Previous Positions

Acting Instructor, Fred Hutchinson Cancer Research Center
Assistant Professor and Attending Physician, Children's Hospital and Regional Medical Center, Pediatric Hematology and Oncology
Assistant Member, Fred Hutchinson Cancer Research Center, Clinical Research Division, Pediatric Oncology/Stem Cell Transplantation
Assistant Professor, University of Washington, School of Medicine, Pediatrics, Pediatric Hematology and Oncology, Stem Cell Transplantation

Funding

  • National Institutes of Health (NIH): R01, Administrative Supplement to current R01, Biology and Prognostic Implications of FLT3 Mutations in AML, 2009 to 2010.
  • Children's Oncology Group: Molecular Assessment of Minimal Risk in Acute Promyelocytic Leukemia, 2009 to 2010.
  • National Institutes of Health (NIH): TARGET Supplement to the Children's Oncology Group Chair's Grant, 2009 to 2011.
  • Fred Hutchinson Cancer Research Center and National Institute of Health: Pilot Study Single Cell Genomic Profiling in Cancer, 2009 to 2010.
  • Fred Hutchinson Cancer Research Center and CCEH: Pilot Study Validating Susceptibility Genes for Acute Myeloid Leukemia, 2009 to 2010.
  • Children's Oncology Group: COG Scientific Committee Chair, 2009 to 2010.
  • National Cancer Institute/ National Children's Cancer Foundation: Biomarkers for Risk Identification and Risk-Based Therapy in Pediatric AML, 2008 to 2010.
  • Seattle Children's: Alterations of DNA Repair Pathway in Regulating Homologous Recombination in AML, 2008 to 2010.
  • Seattle Children's: Biologic and Clinical Implications of a s-SHIP Expression in Pediatric Leukemias, 2007 to 2010.
  • National Institutes of Health (NIH): RO-1, Biology and Prognostic Implications of FLT3 Mutations in AML, 2005 to 2010.
  • National Institutes of Health (NIH): R-21, Accurate Prediction of Early Relapse in Pediatric AML, 2004 to 2006.
  • Children's Oncology Group: COG Translational Research Award, 2004 to 2006.
  • National Institutes of Health (NIH): R-21, Prognostic Implications of FLT3 Mutations in AML, 2003 to 2006.
  • Children's Oncology Group: COG Young Investigator Award, 2001 to 2002.
  • NIH/University of Washington: Child Health Research Center Award, 2000 to 2002.
  • Jose Carreras Leukemia Foundation: Jose Carrera's International Leukemia Foundation, Young Investigator Award, 2000 to 2003.
  • National Institutes of Health/FHCRC: K-12 Translational Research Award, 2000 to 2002.

 

Recent Publications

2013
Mortland, L, Alonzo TA, Walter RB, Gerbing RB, Mitra AK, Pollard JA, Loken MR, Hirsch B, Raimondi S, Franklin J et al..  2013.  Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin-Containing Chemotherapy.. Clinical cancer research : an official journal of the American Association for Cancer Research. 19(6):1620-1627. Abstract
Gudgeon, CJ, Harrington KH, Laszlo GS, Alonzo TA, Gerbing RB, Gamis AS, Raimondi SC, Hirsch BA, Meshinchi S, Walter RB.  2013.  High expression of neutrophil elastase predicts improved survival in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.. Leukemia & lymphoma. 54(1):202-204.
2012
Foss, EJ, Radulovic D, Stirewalt DL, Radich J, Sala-Torra O, Pogosova-Agadjanyan EL, Hengel SM, Loeb KR, Deeg HJ, Meshinchi S et al..  2012.  Proteomic Classification of Acute Leukemias by Alignment-Based Quantitation of LC-MS/MS Data Sets.. Journal of proteome research. 11(10):5005-10. Abstract
Loken, MR, Alonzo TA, Pardo L, Gerbing RB, Raimondi SC, Hirsch BA, Ho PA, Franklin J, Cooper TM, Gamis AS et al..  2012.  Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group.. Blood. Abstract
Meshinchi, S, Hunger SP, Aplenc R, Adamson PC, Jessup MJ.  2012.  Lessons learned from the investigational device exemption review of Children's Oncology Group trial AAML1031.. Clinical cancer research : an official journal of the American Association for Cancer Research. 18(6):1547-54. Abstract
Carpenter, PA, Meshinchi S, Davies SM.  2012.  Transplantation for AML in children.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 18(1 Suppl):S33-9.
Pollard, JA, Alonzo TA, Loken M, Gerbing RB, Ho PA, Bernstein ID, Raimondi SC, Hirsch B, Franklin J, Walter RB et al..  2012.  Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.. Blood. Abstract
Kutny, MA, Moser BK, Laumann K, Feusner JH, Gamis A, Gregory J, Larson RA, Powell BL, Stock W, Willman CL et al..  2012.  FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: A report from the Children's Oncology Group.. Pediatric blood & cancer. Abstract
Cooper, TM, Franklin J, Gerbing RB, Alonzo TA, Hurwitz C, Raimondi SC, Hirsch B, Smith FO, Mathew P, Arceci RJ et al..  2012.  AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: A report from the children's oncology group.. Cancer. 118(3):761-769. Abstract
Gamis, AS, Alonzo TA, Perentesis JP, Meshinchi S.  2012.  Children's Oncology Group's 2013 blueprint for research: Acute myeloid leukemia.. Pediatric blood & cancer. Abstract
Redell, MS, Ruiz MJ, Gerbing RB, Alonzo TA, Lange BJ, Tweardy DJ, Meshinchi S.  2012.  FACS analysis of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: a Children's Oncology Group report.. Blood. Abstract
Creutzig, U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, de Bont E, Harbott J, Hasle H, Johnston D, Kinoshita A et al..  2012.  Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel, on behalf of the AML Committee of the International BFM Study Group.. Blood. Abstract
2011
Ho, PA, Kopecky KJ, Alonzo TA, Gerbing RB, Miller KL, Kuhn J, Zeng R, Ries RE, Raimondi SC, Hirsch BA et al..  2011.  Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric/adult AML: a report from the Children's Oncology Group and SWOG.. Blood. 118(17):4561-6. Abstract
Berman, JN, Gerbing RB, Alonzo TA, Ho PA, Miller K, Hurwitz C, Heerema NA, Hirsch B, Raimondi SC, Lange B et al..  2011.  Prevalence and clinical implications of NRAS mutations in childhood AML: a report from the Children's Oncology Group.. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 25(6):1039-42.
Pui, C-H, Carroll WL, Meshinchi S, Arceci RJ.  2011.  Biology, risk stratification, and therapy of pediatric acute leukemias: an update.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(5):551-65. Abstract
Ho, PA, Kutny MA, Alonzo TA, Gerbing RB, Joaquin J, Raimondi SC, Gamis AS, Meshinchi S.  2011.  Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group.. Pediatric blood & cancer. 57(2):204-9. Abstract
2010
Radhi, M, Meshinchi S, Gamis A.  2010.  Prognostic factors in pediatric acute myeloid leukemia.. Current hematologic malignancy reports. 5(4):200-6. Abstract
Ho, PA, Alonzo TA, Kopecky KJ, Miller KL, Kuhn J, Zeng R, Gerbing RB, Raimondi SC, Hirsch BA, Oehler VG et al..  2010.  Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study.. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 24(5):909-13. Abstract
Pollard, JA, Alonzo TA, Gerbing RB, Ho PA, Zeng R, Ravindranath Y, Dahl G, Lacayo NJ, Becton D, Chang M et al..  2010.  Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.. Blood. 115(12):2372-9. Abstract
Walter, RB, Alonzo TA, Gerbing RB, Ho PA, Smith FO, Raimondi SC, Hirsch BA, Gamis AS, Franklin JL, Hurwitz CA et al..  2010.  High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology group.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(17):2831-8. Abstract
Rubnitz, JE, Inaba H, Dahl G, Ribeiro RC, Bowman PW, Taub J, Pounds S, Razzouk BI, Lacayo NJ, Cao X et al..  2010.  Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.. The lancet oncology. 11(6):543-52. Abstract
Pulikkan, JA, Peramangalam PS, Dengler V, Ho PA, Preudhomme C, Meshinchi S, Christopeit M, Nibourel O, Müller-Tidow C, Bohlander SK et al..  2010.  C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations.. Blood. 116(25):5638-49. Abstract
Ho, PA, Zeng R, Alonzo TA, Gerbing RB, Miller KL, Pollard JA, Stirewalt DL, Heerema NA, Raimondi SC, Hirsch B et al..  2010.  Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.. Blood. 116(5):702-10. Abstract
Phillips, CL, Gerbing R, Alonzo T, Perentesis JP, Harley ITW, Meshinchi S, Bhatla D, Radloff G, Davies SM.  2010.  MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group.. Pediatric blood & cancer. 55(2):248-53. Abstract
Stirewalt, DL, Meshinchi S.  2010.  Receptor tyrosine kinase alterations in AML - biology and therapy.. Cancer treatment and research. 145:85-108. Abstract